Source:http://linkedlifedata.com/resource/pubmed/id/11169964
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
The human epithelial mucin MUC1 is over-expressed in more than 90% of carcinomas of the breast, ovary, and pancreas as well as in some other tumours, making it a potential target for tumour immunotherapy. We have identified several MUC1-derived peptides mapping outside the variable number tandem repeat region that comply with the peptide-binding motif for HLA-A*0201 and that become processed into stable major histocompatibility complex-peptide complexes as assessed by in vitro assays. In A2/K(b) transgenic mice, 3 peptides, namely MUC(79-87) (TLAPATEPA), MUC(167-175) (ALGSTAPPV) and MUC(264-272) (FLSFHISNL) elicit peptide-specific cytotoxic T lymphocyte (CTL) immunity, which protects these mice against a challenge with MUC1, A2/K(b)-expressing tumour cells. These peptides therefore represent naturally processed MUC1-derived CTL epitopes that could be used as components in peptide-based vaccines and for the analysis of anti-MUC1 CTL responses in A*0201-positive patients with MUC1-expressing tumours.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Mucin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
385-92
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11169964-Animals,
pubmed-meshheading:11169964-Epitopes, T-Lymphocyte,
pubmed-meshheading:11169964-HLA-A Antigens,
pubmed-meshheading:11169964-HLA-A2 Antigen,
pubmed-meshheading:11169964-Humans,
pubmed-meshheading:11169964-Immunization,
pubmed-meshheading:11169964-Melanoma, Experimental,
pubmed-meshheading:11169964-Mice,
pubmed-meshheading:11169964-Mice, Transgenic,
pubmed-meshheading:11169964-Mucin-1,
pubmed-meshheading:11169964-Peptide Fragments,
pubmed-meshheading:11169964-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11169964-Tandem Repeat Sequences
|
pubmed:year |
2001
|
pubmed:articleTitle |
Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
|
pubmed:affiliation |
Imperial Cancer Research Fund, Breast Cancer Biology Group, Guy's Hospital, London, United Kingdom.
|
pubmed:publicationType |
Journal Article
|